Increased extracellular brain glutamate has been implicated in the pathophysiology of human refractory temporal lobe epilepsy (TLE), but the cause of the excessive glutamate is unknown. Prior studies by us and others have shown that the glutamate degrading enzyme glutamine synthetase (GS) is deficient in astrocytes in the epileptogenic hippocampal formation in a subset of patients with TLE. We have postulated that the loss of GS in TLE leads to increased glutamate in astrocytes with elevated concentrations of extracellular glutamate and recurrent seizures as the ultimate end-points. Here we test the hypothesis that the deficiency in GS leads to increased glutamate in astrocytes. Rats were chronically infused with methionine sulfoximine (MSO, n = 4) into the hippocampal formation to induce GS deficiency and recurrent seizures. A separate group of rats was infused with 0.9% NaCl (saline) as a control (n = 6). At least 10 days after the start of infusion, once recurrent seizures were established in the MSO-treated rats, the concentration of glutamate was assessed in CA1 of the hippocampal formation by immunogold electron microscopy. The concentration of glutamate was 47% higher in astrocytes in the MSO-treated vs. saline-treated rats (p = 0.02), and the ratio of glutamate in astrocytes relative to axon terminals was increased by 74% in the MSO-treated rats (p = 0.003). These data support our hypothesis that a deficiency in GS leads to increased glutamate in astrocytes. We additionally propose that the GS-deficient astrocytes in the hippocampal formation in TLE lead to elevated extracellular brain glutamate either through decreased clearance of extracellular glutamate or excessive release of glutamate into the extracellular space from these cells, or a combination of the two.
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Introduction
Temporal lobe epilepsy (TLE) is one of the most common types of drug-resistant epilepsies in humans, and more efficacious therapies for this disorder are therefore needed (Hauser et al., 1991) . A better understanding of the molecular and cellular mechanisms that cause drugresistant TLE is likely to facilitate the discovery of such therapies.
Several observations suggest that metabolic perturbation of glutamatergic neurotransmission may be important in the causation of TLE. Firstly, patients with drug-resistant TLE have a five-fold increase in extracellular glutamate in the epileptogenic vs. the nonepileptogenic hippocampal formation interictally (i.e. several hours away from seizures) (Cavus et al., 2005) . Secondly, extracellular glutamate in the epileptogenic hippocampal formation of these patients increases six-fold above the interictal level during a seizure and remains elevated for several hours after the cessation of the seizure (During and Spencer, 1993) . Finally, administration of glutamate and glutamate analogues to laboratory animals causes seizures and brain damage similar to that of human TLE (Nadler and Cuthbertson, 1980; Nadler et al., 1978; Olney, 1978; Olney et al., 1972 Olney et al., , 1986 . Hence, it has been postulated that increased extracellular glutamate is implicated in the pathophysiology of seizures and brain damage in TLE (Gloor, 1991; Olney et al., 1986) .
We and others have previously reported that glutamine synthetase (GS) is severely deficient in a subpopulation of astrocytes in the hippocampal formation in human TLE (Eid et al., 2004; van der Hel et al., 2005) . The etiology of the GS deficiency in TLE is not known, but may involve factors such as free radical damage to the enzyme Neurobiology of Disease 47 (2012) [331] [332] [333] [334] [335] [336] [337] 
